Discovery Labs to Present at the 25th Annual Piper Jaffray Health Care Conference

    Discovery Labs to Present at the 25th Annual Piper Jaffray Health Care

PR Newswire

WARRINGTON, Pa., Nov. 21, 2012

WARRINGTON, Pa., Nov. 21, 2012 /PRNewswire/ --Discovery Laboratories, Inc.
(NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new
standard in respiratory critical care, today announced that management will
present an overview and update on the Company's business at the 25^th Annual
Piper Jaffray Health Care Conference on Tuesday, December 3, 2013 at 1:10 PM
ET. The conference will be held at the New York Palace Hotel in New York, New

Discovery Laboratories, Inc. is a specialty biotechnology company focused on
advancing a new standard in respiratory critical care. Discovery Labs'
technology platform includes its novel proprietary KL4 surfactant, a
synthetic, peptide-containing surfactant that is structurally similar to
pulmonary surfactant, and its proprietary drug delivery technologies being
developed to enable efficient delivery of aerosolized KL4 surfactant and other
inhaled therapies. Discovery Labs' strategy is initially focused on
neonatology and improving the management of respiratory distress syndrome
(RDS) in premature infants. Discovery Labs believes that its RDS product
portfolio has the potential to become the new standard of care for RDS and,
over time, enable the treatment of a significantly greater number of premature
infants who could benefit from surfactant therapy but are currently not

For more information, please visit the Company's website at

Forward-Looking Statements
To the extent that statements in this press release are not strictly
historical, all such statements are forward-looking, and are made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially from the
statements made. Examples of such risks and uncertainties are described in
Discovery Labs' filings with the Securities and Exchange Commission including
the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments

SOURCE Discovery Laboratories, Inc.

Contact: John Tattory, Vice President, Finance: 215.488.9418 or; Michael Rice, LifeSci Advisors: 646.597.6979 or
Press spacebar to pause and continue. Press esc to stop.